1,2-dihydro-1-(4-fluorobenzyl)-2-oxopyridine-3-carboxylic acid | 66158-41-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,2-dihydro-1-(4-fluorobenzyl)-2-oxopyridine-3-carboxylic acid
• 英文别名: (4-fluorobenzyl)-2-oxopyridine-3-carboxylic acid；1-(4-Fluor-benzyl)-1,2-dihydro-2-oxo-nicotinsaeure；1-(4-Fluoro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid；1-[(4-fluorophenyl)methyl]-2-oxopyridine-3-carboxylic acid
• CAS: 66158-41-6
• 化学式: C₁₃H₁₀FNO₃
• mdl: MFCD09033897
• 分子量: 247.226
• InChiKey: KFUPGHOUJJNVJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,2-dihydro-1-(4-fluorobenzyl)-2-oxopyridine-3-carboxylic acid 在 copper(l) iodide 、 溴 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 lithium bromide 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.5h， 生成 5-bromo-N-cycloheptyl-1,2-dihydro-1-(4-fluorobenzyl)-4-(4-methoxyphenyl)-2-oxopyridine-3-carboxamide
  参考文献：
  名称：

  Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system

  摘要：

  The endocannabinoid system (ECS) represents one of the major neuromodulatory systems involved in different physiological and pathological processes. Multi-target compounds exert their activities by acting via multiple mechanisms of action and represent a promising pharmacological modulation of the ECS. In this work we report 4-substituted and 4,5-disubstituted 1,2-dihydro-2-oxo-pyridine-3-carboxamide derivatives with a broad spectrum of affinity and functional activity towards both cannabinoid receptors and additional effects on the main components of the ECS. In particular compound B3 showed high affinity for CB1R (K-i = 23.1 nM, partial agonist) and CB2R (K-i = 6.9 nM, inverse agonist) and also significant inhibitory activity (IC50 = 70 nM) on FAAH with moderate inhibition of ABHD12 (IC50 = 2.5 mu M). Compounds B4, B5 and B6 that act as full agonists at CB1R and as partial agonists (B5 and B6) or antagonist (B4) at CB2R, exhibited an additional multi-target property by inhibiting anandamide uptake with sub-micromolar IC50 values (0.28-0.62 mu M). The best derivatives showed cytotoxic activity on U937 lymphoblastoid cells. Finally, molecular docking analysis carried out on the three-dimensional structures of CB1R and CB2R and of FAAH allowed to rationalize the structure-activity relationships of this series of compounds. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.05.019
• 作为产物：
  描述：

  methyl 1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 1.5h， 生成 1,2-dihydro-1-(4-fluorobenzyl)-2-oxopyridine-3-carboxylic acid
  参考文献：
  名称：

  Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

  摘要：

  Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC(50) value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors Such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent anti proliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC(50) values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTI-16 human gastric carcinoma xenograft model.

  DOI：

  10.1021/jm800476q

文献信息

• [EN] PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIDINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CEPHALON INC

  公开号：WO2015100117A1

  公开（公告）日：2015-07-02

  The invention is directed to pyrazolo[1,5-a]pyridine derivatives and their use as AXL and c-MET kinase inhibitors.

  这项发明涉及吡唑并[1,5-a]吡啶衍生物及其作为AXL和c-MET激酶抑制剂的用途。
• [EN] HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS<br/>[FR] AMIDES D'ACIDE CARBOXYLIQUE HÉTÉROCYCLIQUES COMME INHIBITEURS DE PDK1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011131741A1

  公开（公告）日：2011-10-27

  The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

  本发明涵盖了通式（1）中的化合物，其中基团R1至R4、Qa、Qb、QH、L和n的定义如权利要求书中所述，这些化合物适用于治疗以细胞过度或异常增殖为特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的使用。
• NEW CHEMICAL COMPOUNDS
  申请人：Engelhardt Harald

  公开号：US20120094976A1

  公开（公告）日：2012-04-19

  The present invention encompasses compounds of general formula (1) wherein the groups R 1 to R 4 , Q a , Q b , Q H , L and n are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

  本发明涵盖了一般式（1）中的化合物，其中基团R1至R4、Qa、Qb、QH、L和n的定义如权利要求书中所述，这些化合物适用于治疗由细胞过度或异常增殖特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的用途。
• [EN] 1H - IMIDAZO [4, 5 - C] QUINOLINES<br/>[FR] 1H-IMIDAZO[4,5-C]QUINOLÉINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011144622A1

  公开（公告）日：2011-11-24

  The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.

  本发明涵盖了一般式（1）的化合物，其中基团R1至R7、Qa、Qb、L、n和m的定义如权利要求书中所述，适用于治疗由细胞过度或异常增殖特征的疾病，包括含有这种化合物的药物制剂以及它们作为药物的用途。
• 一种烟酰胺类衍生物及其制备方法和用途
  申请人：沈阳药科大学

  公开号：CN108239068B

  公开（公告）日：2020-09-08

  本发明公开了一类新化合物N‑3‑(4‑R2取代)‑(1‑R1取代苯并咪唑)‑(1’‑R3取代)‑2’‑氧代‑烟酰胺类衍生物及其制备方法与应用。所述化合物的结构式如式I所示，式I中，R1、R2、R3如权利要求和说明书所述。本发明的化合物具有很好的抗糖尿病活性，在制备抗糖尿病药物领域，可以用作治疗糖尿病的治疗剂。